NCT06939946

Brief Summary

It is often challenging to tell apart the parathyroid glands from the surrounding area such as lymph nodes, fat and thyroid tissue. If the surgeons are not able to tell where the parathyroid glands are, they might accidentally be removed or damaged. This can lead to complications such as hypocalcemia (low calcium level) requiring treatment and sometimes lead to longer hospital stay. This study is designed to test a new method (a non-invasive hand-held imaging device) to assist surgeons in identifying the parathyroid glands, in order to decrease the rate of post-operative complication.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Sep 2023

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2023

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

April 11, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 23, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 28, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 28, 2025

Completed
Last Updated

December 19, 2025

Status Verified

December 1, 2025

Enrollment Period

2 years

First QC Date

April 11, 2025

Last Update Submit

December 12, 2025

Conditions

Keywords

Thyroid surgeryParathyroid fluorescenceIndocyanine Green

Outcome Measures

Primary Outcomes (1)

  • Number of Parathyroid Glands identified by the imager.

    Once the thyroid gland is removed the imager will be used to confirm the presence of 4 parathyroid glands, and will be compared to the number of parathyroid glands seen by naked eye.

    10 minutes prior to injection of ICG

Secondary Outcomes (2)

  • Perfusion assessment using ICG angiography.

    10 minutes after ICG injection.

  • Measurement of Parathyroid hormone and calcium levels.

    1 day after the surgery.

Study Arms (1)

Parathyroid auto-florescence imaging

EXPERIMENTAL

Patients undergoing open thyroid surgery

Device: Parathyroid auto-fluorescence imagingDrug: Indocyanine green

Interventions

All enrolled patients for thyroid surgery, once the thyroid gland is removed the device will be used to identify the parathyroid glands.

Also known as: hANDY-i, Hand-Held Imager
Parathyroid auto-florescence imaging

For a select group of patients when deemed necessary by the surgeon, and when one or more parathyroid gland appear to be de vascularized ICG will be administered, A dosage of 5 mg will be injected into a peripheral IV line, followed by fluorescence imaging to determine the perfusion status of the gland.

Also known as: ICG
Parathyroid auto-florescence imaging

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of thyroid tumors, or other conditions requiring thyroid surgery where frozen section biopsy of PTGs is deemed necessary under the surgeon's estimation.
  • Plan for surgical resection of pathological PTGs.
  • Subject age 18 - 70 yo.
  • Subject agreement to participate

You may not qualify if:

  • Not eligible for endocrine surgeries
  • Plan for biopsy only of thyroid tumor (likely difficult to obtain sufficient tissue for both pathology analysis and study assessment)
  • Subject age younger than 18 yo or older than 70 yo
  • Subject refusal to participate
  • Subject cognitively impaired and/or unable to provide assent.
  • Allergy to indocyanine green and iodine.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

Location

Related Publications (2)

  • Ali KM, Wolfe SA, Nagururu NV, Seo S, Han SM, Kim Y, Oh E, Kim DY, Ning B, Lee SY, Cha RJ, Tufano RP, Russell JO. Parathyroid gland detection using an intraoperative autofluorescence handheld imager - early feasibility study. Front Endocrinol (Lausanne). 2023 Jul 24;14:1190282. doi: 10.3389/fendo.2023.1190282. eCollection 2023.

  • Kim Y, Lee HC, Kim J, Oh E, Yoo J, Ning B, Lee SY, Ali KM, Tufano RP, Russell JO, Cha J. A coaxial excitation, dual-red-green-blue/near-infrared paired imaging system toward computer-aided detection of parathyroid glands in situ and ex vivo. J Biophotonics. 2022 Aug;15(8):e202200008. doi: 10.1002/jbio.202200008. Epub 2022 Apr 20.

MeSH Terms

Conditions

Thyroid Diseases

Interventions

Indocyanine Green

Condition Hierarchy (Ancestors)

Endocrine System Diseases

Intervention Hierarchy (Ancestors)

IndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Kaitlyn Frazier, MD

    Johns Hopkins University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 11, 2025

First Posted

April 23, 2025

Study Start

September 1, 2023

Primary Completion

August 28, 2025

Study Completion

August 28, 2025

Last Updated

December 19, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Data review for each subject will be completed shortly after enrollment. The research data will not include the participant's contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by research staff will be secured and password protected. At the end of the study, all study databases will be archived at Johns Hopkins Hospital.

Locations